Highest development stage: Phase 2

Development status: Inactive (as of 2023

Gram-positive activity

Gram-negative activity

Combination therapy

Mechanism of Action/Target pathogen: Inhibits leucyl-tRNA synthetase (LeuRS) blocking protein synthesis, active against Enterobacteriaceae, Peudomonas aeruginosa and Mycobacterium abscessus

Reason dropped: Phase 2 trial terminated due to resistance concerns

Additional information: Synthetic compound. Rapid emergence of resistance; developed in combination for nontuberculous mycobacterium infections